NDAORALTABLETPriority Review
Approved
Jun 1951
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 2d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PHENURONE (phenacemide) is an oral tablet small molecule approved in 1951 for seizure management. The specific mechanism of action and current indications are not documented in available records, reflecting its age and historical status in the market.
LOE Approaching
This legacy product approaching loss of exclusivity operates in a contracted market with minimal team investment; commercial roles focus on managed care negotiations and niche prescriber relationships rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Careers linked to PHENURONE are suited for professionals seeking stable, specialized roles in legacy product management and niche therapeutic areas rather than high-growth trajectories. Opportunities emphasize managed care negotiations, specialist engagement, and compliance over field sales or launch activities.
Brand Manager (Managed Care)Medical Science Liaison (Specialty Neurology)
Worked on PHENURONE at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.